Authors: Prof Dr S M Khodeza Nahar Begum
Institution: BSH
The use of neoadjuvant therapy in managing early-stage invasive breast cancer is on the rise. There is a need to standardize the evaluation of post-neoadjuvant therapy breast specimens in routine clinical practice. Tools such as Residual Cancer Burden (RCB) utilize pathological characteristics of treated tumors to assess long-term outcomes. Neoadjuvant chemotherapy requires a thorough understanding of the specimen, along with knowledge of the patient’s clinical disease, radiologic findings, and treatment course. Effective communication between specialists is crucial in optimizing patient care.
Reconstructing the gross, radiologic, and histopathologic findings is essential for estimating the Residual Cancer Burden (RCB). As pathologists, our role is critically important to our clinical colleagues and, most importantly, to the patients they treat. Therefore, our aim is to provide the most structured and valuable information possible.
N/A
This discussion aims to emphasize the importance of a unified approach to standardizing the grossing and reporting of breast specimens in the neoadjuvant setting, ultimately improving patient outcomes.